Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH-Reference-Cited by-同舟云学术

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Author:

Harrison Stephen A.¹²,Bashir Mustafa³,Moussa Sam E.⁴,McCarty Kevin⁵,Pablo Frias Juan⁶,Taub Rebecca⁷,Alkhouri Naim⁸

Affiliation:

1. Radcliffe Department of Medicine University of Oxford Oxford United Kingdom

2. Department of Medicine Pinnacle Clinical Research San Antonio TX USA

3. Department of Radiology Center for Advanced Magnetic Resonance Duke University Medical Center Durham NC USA

4. Department of Medicine University of Arizona for Medical Sciences Tuscon AZ USA

5. Medpace Cincinnati OH USA

6. Department of Medicine University of California San Diego CA USA

7. Madrigal Pharmaceuticals West Conshohocken PA USA

8. Arizona Liver Health Phoenix AZ USA

Publisher

Wiley

Subject

Hepatology

Link

Reference26 articles.

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resmetirom;Hospital Pharmacy;2024-09-05